BI
ONCT

BVF Inc’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

BVF Inc’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,758
Closed -$5.91M – 60
2018
Q2 		$5.91M Sell
2,758
-1,597
-37% -$4.05M 0.58% 39
2018
Q1 		$10.8M Sell
4,355
-3,555
-45% -$7.92M 1.1% 26
2017
Q4 		$14.1M Sell
7,910
-7
-0.1% -$10.1K 1.7% 18
2017
Q3 		$9.11M Hold
7,917
– – 1.16% 25
2017
Q2 		$5.86M Hold
7,917
– – 0.91% 25
2017
Q1 		$5.39M Hold
7,917
– – 0.92% 25
2016
Q4 		$5.85M Sell
7,917
-306
-4% -$327K 1.18% 21
2016
Q3 		$9.01M Hold
8,223
– – 1.7% 18
2016
Q2 		$6.33M Hold
8,223
– – 1.35% 20
2016
Q1 		$5.76M Buy
8,223
+249
+3% +$216K 1.42% 21
2015
Q4 		$7.81M Buy
7,974
+279
+4% +$369K 1.33% 21
2015
Q3 		$8.19M Hold
7,695
– – 1.65% 18
2015
Q2 		$15.8M Sell
7,695
-242
-3% -$344K 2.79% 14
2015
Q1 		$7.51M Hold
7,937
– – 1.57% 18
2014
Q4 		$8.11M Buy
+7,937
New +$7.08M 1.58% 18

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BVF Inc's ONCT Position: Q3 2018 in Review

BVF Inc sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2018, closing a stake of 2,758 shares — an estimated $5.91M sold.

BVF Inc first reported a position in ONCT in Q4 2014 and held it in 15 quarters. The position peaked at $15.8M in Q2 2015. 48 funds tracked by Wall St. Rank hold ONCT as of Q3 2018.

  • BVF Inc reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • BVF Inc sold 2,758 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $5.91M.
  • BVF Inc first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2014 and held it in 15 quarters.
  • BVF Inc's Oncternal Therapeutics, Inc. Common Stock position peaked at $15.8M in Q2 2015.
  • 48 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2018.

Based on BVF Inc's 13F filing for Q3 2018, filed 14 Nov 2018.